Participation of OGYEI TEI in EUnetHTA

Dr Horvath Beatrix

Dr Szerencses Viktoria

EUnetHTA Joint Action 1 (2010-2012)

- WP1 - Coordination
- WP2 - Dissemination
- WP3 - Evaluation
- WP4 - Core HTA
- **WP5 - Relative Effectiveness Assessment of Pharmaceuticals**
- **WP6 - Information Management System**
- **WP7 - New Technologies**
- WP8 - Strategy and Business Model Development

EUnetHTA Joint Action 2 (2012-2015)

- WP1 - Coordination
- WP2 - Dissemination
- **WP3 - Evaluation**
- WP4 - Testing collaborative production of HTA information for national adaptation and reporting
- **WP5 - Applying the HTA Core Model for Rapid Assessment for national adaptation and reporting**
- WP6 - Information Management Infrastructure and Services (IMIS)
- **WP7 - Methodology development and evidence generation: Guidelines and pilots production**
- WP8 - Maintenance of HTA Core Model infrastructure to support shared production and sharing of HTA information

JA2 Work Package 3 (WP3)

- We created an excel model which can automatically calculate the aggregated data provided by the Secretariat.
- The output of this calculation shows the hours and costs per WP and other divisions are also visible.

- The output of this calculation shows the hours and costs:
  - per WP
  - per WP identifier number
  - of each WP were calculated country-wise
  - of the function of the staff were also calculated per each WP
  - were listed for each scenario (including the separate components of each scenario)

JA2 Work Package 5 (WP5)

We took part in five pilot rapid assessments as dedicated reviewer:

Strand A

- Pilot rapid assessments of two pharmaceuticals (sorafenib, ramucirumab)
- Three assessments were used for background information in Hungarian local reports (sorafenib, ramucirumab, canagliflozin)

Strand B

- Pilot rapid assessments of three medical devices

JA2 Work Package 7 (WP7)

We took part in:

- Early dialogues (ED) of three medicines
  SEED Consortium: ED of three pharmaceuticals and one medical device
- the work of SG2 and SG3 as reviewers
- the creation of a uniform data template for submissions (both for pharmaceauticals and medical devices) that includes the evidence requirements from European HTA organisations (SG4)

WP7	
Subgroup 1	Subgroup 2
1. Early Dialogues for drugs and non-drug technologies	Additional Evidence Generation
2. Disease specific guidelines	
Subgroup 3	Subgroup 4
Elaborate 1. templates 2. process for elaborating guidelines	Development of manufacturers' template for REA

Joint Action 3 – planned participation

WP2

- Review of joint assessments

WP3

- Project 1: Early Dialogue

WP5

- Core partners in national adaptation

Experiences gained in the JAs

Pros

strong competencies in the filed of HTA in the region

working in international environment

many positive feedback for the contribution done

Cons

national capacities are limited

frequent change in the staff (expert

To develop:

Effective communication with the partners (other HTA agencies, it is started with NICE)

Establish the European HTA Agency as a network organisation with the participation od the national HTA bodies

Thank You for your attention!